Annovis Bio CEO to Present Alzheimer's Multi-Protein Research at Fierce Biotech Week 2026

Annovis Bio (NYSE: ANVS), a biotechnology company advancing treatments for neurodegenerative diseases, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will focus on the scientific rationale for treating Alzheimer's disease as a multi-protein disorder and detail Annovis' approach of targeting multiple neurotoxic proteins simultaneously through its lead drug candidate, buntanetap.

Buntanetap, an investigational once-daily oral therapy, inhibits the translation of several neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. This approach aims to address the underlying causes of neurodegeneration, potentially halting disease progression and improving cognitive and motor functions in patients. The drug is currently in a pivotal Phase 3 clinical trial, representing a significant step toward a potential new treatment for Alzheimer's and Parkinson's diseases.

The announcement underscores the growing recognition of Alzheimer's as a complex disease involving multiple protein pathologies, rather than a single target. By targeting several proteins at once, Annovis hopes to overcome limitations of therapies that address only one aspect of the disease. The presentation at Fierce Biotech Week, a major industry event, provides a platform to discuss these scientific insights with peers and investors.

For more details, the full press release is available at https://ibn.fm/kZ2Z4. Additional information about Annovis Bio can be found on its website at www.annovisbio.com and through its newsroom at https://ibn.fm/ANVS.

Annovis Bio, headquartered in Malvern, Pennsylvania, is a Phase 3 clinical-stage biotechnology company developing treatments for Alzheimer's disease and Parkinson's disease. The company's lead candidate, buntanetap (formerly posiphen), is designed to inhibit the translation of multiple neurotoxic proteins, offering a novel approach to tackling neurodegeneration. By addressing the root causes of these diseases, Annovis aims to improve outcomes for patients suffering from these debilitating conditions.